Icon

OFEV (nda205832)- (EQ 100MG BASE,EQ 150MG BASE)

NINTEDANIB ESYLATE BOEHRINGER INGELHEIM
EQ 100MG BASE,EQ 150MG BASE
Yes No
2029-Dec-07 2019-Oct-15
2021-Oct-15 None
None No
OFEV is a kinase inhibitor indicated in adults for: • Treatment of idiopathic pulmonary fibrosis (IPF). • Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype • Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
0 4 0
Total Other Developers 12
Drugs with Suitability No
EQ 100MG BASE ** ** - - -
EQ 150MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.